PT1141014E - Variante mutante do factor de crescimento semelhante a insulina (igf-i) - Google Patents

Variante mutante do factor de crescimento semelhante a insulina (igf-i)

Info

Publication number
PT1141014E
PT1141014E PT00901397T PT00901397T PT1141014E PT 1141014 E PT1141014 E PT 1141014E PT 00901397 T PT00901397 T PT 00901397T PT 00901397 T PT00901397 T PT 00901397T PT 1141014 E PT1141014 E PT 1141014E
Authority
PT
Portugal
Prior art keywords
igf
insulin
variation
growth factor
disorder
Prior art date
Application number
PT00901397T
Other languages
English (en)
Portuguese (pt)
Inventor
Dubaquie Yves
Paul J Fielder
Henry B Lowman
Deborah L Mortensen
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PT1141014E publication Critical patent/PT1141014E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PT00901397T 1999-01-06 2000-01-05 Variante mutante do factor de crescimento semelhante a insulina (igf-i) PT1141014E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11501099P 1999-01-06 1999-01-06
US17026199P 1999-12-09 1999-12-09

Publications (1)

Publication Number Publication Date
PT1141014E true PT1141014E (pt) 2005-04-29

Family

ID=26812755

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00901397T PT1141014E (pt) 1999-01-06 2000-01-05 Variante mutante do factor de crescimento semelhante a insulina (igf-i)

Country Status (12)

Country Link
US (3) US6403764B1 (de)
EP (1) EP1141014B1 (de)
JP (2) JP3971108B2 (de)
AT (1) ATE284415T1 (de)
AU (1) AU762351B2 (de)
CA (1) CA2356109C (de)
DE (1) DE60016560T2 (de)
DK (1) DK1141014T3 (de)
ES (1) ES2234560T3 (de)
IL (2) IL143866A0 (de)
PT (1) PT1141014E (de)
WO (1) WO2000040613A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875741B2 (en) * 1998-09-02 2005-04-05 Renuka Pillutla Insulin and IGF-1 receptor agonists and antagonists
US7173005B2 (en) * 1998-09-02 2007-02-06 Antyra Inc. Insulin and IGF-1 receptor agonists and antagonists
DE60016560T2 (de) * 1999-01-06 2005-12-15 Genentech, Inc., South San Francisco Mutierte variante des insulin-ähnlichen wachstumsfaktor-i (igf-i)
US20020143725A1 (en) * 2001-01-29 2002-10-03 Smith Robin Young Systems, methods and computer program products for determining parameters for chemical synthesis and for supplying the reagents, equipment and/or chemicals synthesized thereby
US7250950B2 (en) * 2001-01-29 2007-07-31 Symyx Technologies, Inc. Systems, methods and computer program products for determining parameters for chemical synthesis
US6849718B2 (en) * 2001-03-20 2005-02-01 Dana Farber Cancer Institute, Inc. Muteins of hypoxia inducible factor alpha and methods of use thereof
US20040048925A1 (en) * 2002-09-09 2004-03-11 Wiley David B. Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
AU2004290070A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
MY146381A (en) * 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
EP1674113A1 (de) * 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Konjugate von insulinähnlichem Wachstumfaktor-1 und Poly(Ethylenglykol)
BRPI0606398A (pt) 2005-01-05 2008-03-11 Biogen Idec Inc moléculas de criptoligação
DK2241575T3 (en) 2005-01-07 2015-08-24 Regeneron Pharma IGF-1 fusion polypeptides and therapeutic uses thereof
TWI406870B (zh) 2005-02-21 2013-09-01 Chugai Pharmaceutical Co Ltd A method of making a protein using hamster IGF-1
UA97953C2 (uk) * 2006-06-09 2012-04-10 Новартіс Аг Стабілізовані поліпептиди інсуліноподібного фактора росту
CN101484469B (zh) * 2006-08-31 2012-12-12 弗·哈夫曼-拉罗切有限公司 生产胰岛素样生长因子-ⅰ的方法
CL2007002502A1 (es) 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
CA2671298C (en) 2007-01-25 2020-07-28 F. Hoffmann-La Roche Ag Use of igfbp-7 in the assessment of heart failure
JP2010520204A (ja) * 2007-03-02 2010-06-10 アムジェン インコーポレイテッド 腫瘍疾患を治療するための方法および組成物
US7994127B2 (en) * 2007-06-08 2011-08-09 Massachusetts Institute Of Technology Treatment of rett syndrome
ES2388827T3 (es) * 2008-04-03 2012-10-19 F. Hoffmann-La Roche Ag Uso de variantes de IGF-I PEGiladas para el tratamiento de trastornos neuromusculares
AU2009231186A1 (en) * 2008-04-03 2009-10-08 F. Hoffmann-La Roche Ag Pegylated insulin-like-growth-factor assay
PL219335B1 (pl) * 2008-07-04 2015-04-30 Inst Biotechnologii I Antybiotyków Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna
WO2011011072A2 (en) * 2009-07-22 2011-01-27 Ipsen Pharma S.A.S. Analogues of insulin-like growth factor-1 (igf-1) having amino acid substitution at position 59
AU2010294192A1 (en) 2009-09-10 2012-04-05 Lonza Biologics Plc Method and system for polypeptide purification
US20110152188A1 (en) * 2009-12-23 2011-06-23 Hanns-Christian Mahler Pharmaceutical compositions of igf/i proteins
TW201217527A (en) 2010-07-09 2012-05-01 Biogen Idec Hemophilia Inc Processable single chain molecules and polypeptides made using same
WO2013012733A1 (en) 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
DK2802606T3 (en) 2012-01-10 2018-06-25 Biogen Ma Inc INCREASE TRANSPORT OF THERAPEUTIC MOLECULES OVER THE BLOOD-BRAIN BARRIER
WO2014097116A1 (en) 2012-12-18 2014-06-26 Novartis Ag Stabilized insulin-like growth factor polypeptides
SG10201707600XA (en) 2013-03-15 2017-11-29 Biogen Ma Inc Factor ix polypeptide formulations
CN104293766A (zh) * 2013-07-15 2015-01-21 四川农业大学 山羊IGFBP3基因cDNA编码序列克隆的方法
EA201690490A1 (ru) 2013-10-02 2016-07-29 Новартис Аг Миметики инсулиноподобного фактора роста для применения в терапии
UY35874A (es) 2013-12-12 2015-07-31 Novartis Ag Un proceso para la preparación de una composición de proteínas pegiladas
MA46146A1 (fr) 2014-01-20 2020-12-31 Hanmi Pharm Ind Co Ltd Insuline a action prolongée et utilisation associée
WO2015111008A2 (en) 2014-01-27 2015-07-30 Novartis Ag Biomarkers predictive of muscle atrophy, method and use
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
AR100695A1 (es) 2014-05-30 2016-10-26 Hanmi Pharm Ind Co Ltd Composición para el tratamiento de diabetes mellitus que comprende insulina y un agonista dual glp-1 / glucagón
CN107636159B (zh) 2015-02-04 2022-06-14 百时美施贵宝公司 选择治疗性分子的方法
US11077132B2 (en) 2015-02-04 2021-08-03 F. Hoffmann-La Roche Ag Tau antisense oligomers and uses thereof
UY36870A (es) * 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
BR112019005637A2 (pt) 2016-09-23 2019-07-30 Hanmi Pharm Ind Co Ltd análogos da insulina com afinidade reduzida para o receptor de insulina e seu uso
WO2018174668A2 (ko) 2017-03-23 2018-09-27 한미약품 주식회사 인슐린 수용체와의 결합력이 감소된 인슐린 아날로그의 결합체 및 이의 용도
CN117384275B (zh) * 2023-12-13 2024-03-15 北京科为博生物科技有限公司 胰岛素样生长因子突变体igf1m及其应用

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US3721252A (en) 1971-04-01 1973-03-20 Catheter And Instr Corp Spring guide washer
US4511503A (en) 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
IL71991A (en) 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
WO1985000831A1 (en) 1983-08-10 1985-02-28 Amgen Microbial expression of insulin-like growth factor
AU598205B2 (en) 1985-08-22 1990-06-21 Gropep Pty Ltd Peptide analogues of mammalian insulin-like growth factor-1
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
SE8505922D0 (sv) 1985-12-13 1985-12-13 Kabigen Ab Construction of an igg binding protein to facilitate downstream processing using protein engineering
ATE90690T1 (de) 1987-04-06 1993-07-15 Celtrix Pharma Menschliche somatomedin-traeger-proteinuntereinheiten und verfahren zu ihrer herstellung.
AU607209B2 (en) 1987-04-23 1991-02-28 Monsanto Technology Llc Secretion of insulin-like growth factor-i in e. coli
SE8703625D0 (sv) 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
US4876242A (en) 1987-09-21 1989-10-24 Merck & Co., Inc. Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast
US5470828A (en) 1987-12-24 1995-11-28 Gropep Pty. Ltd. Peptide analogs of insulin-like growth factor II
ATE116335T1 (de) * 1987-12-24 1995-01-15 Gropep Pty Ltd Peptid-analoge vom insulinähnlichen wachstums- faktor 1 (igf-1) oder faktor 2 (igf-2).
DE68905203T2 (de) 1988-02-05 1993-07-22 Ciba Geigy Ag Verwendung von igf i zur herstellung eines praeparates fuer die behandlung von nierenkrankheiten.
US4988675A (en) 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects
DK131988A (da) 1988-03-11 1989-09-12 Erasmus University Igf-bindingsprotein, dna-struktur, der koder for igf-bindingsproteinet og vektor indeholdende denne dna-struktur
US5258287A (en) 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
EP0418230B1 (de) 1988-04-12 1995-12-27 Amgen Boulder Inc. Verfahren zur steigerung und zur hemmung der wirkung eines insulinähnlichen wachstumfaktors
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5534617A (en) 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
GB8826451D0 (en) 1988-11-11 1988-12-14 Sandoz Ltd Improvements in/relating to organic compounds
IL92816A0 (en) 1988-12-22 1990-09-17 Biogrowth Inc Recombinant dna molecules,hosts,processes and human somatomedin carrier protein-like polypeptides
EP0379338A3 (de) 1989-01-17 1991-07-24 Merck & Co. Inc. Menschlicher insulinähnlicher Wachstumsfaktor und seine Herstellung in Hefe
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
US5093317A (en) 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
US5652214A (en) 1989-06-05 1997-07-29 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
GB8920381D0 (en) 1989-09-08 1989-10-25 Greater Glasgow Health Board Treatment of insulin-resistant diabetes
ZA9010332B (en) 1989-12-22 1991-08-28 Ciba Geigy Method of reducing or preventing adverse effect of steroid therapy and compositions therefor
NZ236618A (en) 1990-01-03 1997-06-24 Ciba Geigy Ag Treating and preventing osteoporosis using insulin-like growth factor i (igf i) in conjunction with a bone antiresorptive active compound
US5374620A (en) 1990-06-07 1994-12-20 Genentech, Inc. Growth-promoting composition and its use
US5126324A (en) 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US5364839A (en) 1990-06-18 1994-11-15 Genetics Institute, Inc. Osteoinductive pharmaceutical formulations
US5210017A (en) 1990-11-19 1993-05-11 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
US5593844A (en) 1990-11-19 1997-01-14 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
SE9100099D0 (sv) 1991-01-11 1991-01-11 Kabi Pharmacia Ab Use of growth factor
US5206023A (en) 1991-01-31 1993-04-27 Robert F. Shaw Method and compositions for the treatment and repair of defects or lesions in cartilage
US5187151A (en) 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
EP0575485A1 (de) 1991-03-01 1993-12-29 Dyax Corp. Verfahren zur entwicklung bindender miniproteine
US5206235A (en) 1991-03-20 1993-04-27 Merck & Co., Inc. Benzo-fused lactams that promote the release of growth hormone
US5202119A (en) 1991-06-28 1993-04-13 Genentech, Inc. Method of stimulating immune response
DE69218948T2 (de) 1991-08-01 1997-07-31 Auckland Uniservices Ltd IGF-I zur Verbesserung der neuronale Lage
US6310040B1 (en) 1991-11-08 2001-10-30 Cephalon, Inc. Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
TW267102B (de) 1992-03-13 1996-01-01 Ciba Geigy
SE9201573D0 (sv) 1992-05-19 1992-05-19 Kabi Pharmacia Ab Use of igf-1
NZ280523A (en) 1992-06-12 1997-07-27 Cephalon Inc Administering insulin like growth factor i or iii to reduce peripheral neuropathy not caused by abnormal insulin levels
GB9217696D0 (en) 1992-08-20 1992-09-30 Agricultural & Food Res Use of specific binding molecules
US5273961A (en) 1992-09-22 1993-12-28 Genentech, Inc. Method of prophylaxis of acute renal failure
US5342763A (en) 1992-11-23 1994-08-30 Genentech, Inc. Method for producing polypeptide via bacterial fermentation
ES2097426T3 (es) 1992-12-02 1997-04-01 Hoechst Ag Procedimiento para la obtencion de proinsulina con puentes de cistina correctamente unidos.
CA2132871A1 (en) 1993-01-25 1994-08-04 Alan C. Moses Method for modifying, diagnosing, and screening for igf-i sensitive cell barrier properties
KR960700069A (ko) 1993-01-29 1996-01-19 다니엘 바프네크 상처 치료용 조성물(wound healing composition)
US5457109A (en) 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
KR100354897B1 (ko) 1993-12-23 2003-01-06 노보 노르디스크 에이/에스 성장호르몬방출성을갖는화합물
CN1052730C (zh) 1993-12-23 2000-05-24 诺沃挪第克公司 具有生长激素释放特性的化合物
US5597700A (en) 1994-04-28 1997-01-28 California Research, Llc Method for detecting free insulin-like growth-factor-binding protein 1 and a test device for detecting the ruptures of fetal membranes using the above method
US5444047A (en) 1994-06-16 1995-08-22 Dipasquale; Gene Treatment of arthritic and post-surgical orthopedic conditions with Insulin-like Growth Factor-I
SE9402331D0 (sv) 1994-07-01 1994-07-01 Pharmacia Ab New use
SE9402370D0 (sv) 1994-07-04 1994-07-04 Pharmacia Ab Use of IGF-I
HRP940432B1 (en) 1994-08-05 2003-10-31 Pliva Pharm & Chem Works Dna sequences encoding biosynthetic insulin precursors and process for preparation of insulin
US5712249A (en) 1994-09-08 1998-01-27 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
US5798337A (en) 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
SE9501472D0 (sv) 1995-04-21 1995-04-21 Pharmacia Ab Truncated IGF-I
US5622932A (en) 1995-05-05 1997-04-22 Eli Lilly And Company IGF-1 superagonists
US5741776A (en) 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
US5565428A (en) 1995-05-22 1996-10-15 Genentech, Inc. Method of administration of IGF-I
ES2163020T3 (es) 1995-05-26 2002-01-16 Theratechnologies Inc Analogos quimericos de factor liberador de hormona de crecimiento (grf) de cuerpo graso, provistos de mayor potencia biologica.
TR199701526T1 (xx) 1995-06-07 1998-03-21 Glaxo Group Limited Bir trombopoietin resept�r�ne ba�lanan peptitler ve bile�ikler.
AU6046696A (en) 1995-06-07 1996-12-30 Glaxo Group Limited Peptides and compounds that bind to a receptor
US5958872A (en) 1996-04-01 1999-09-28 Apoptosis Technology, Inc. Active survival domains of IGF-IR and methods of use
WO1997039032A1 (en) 1996-04-17 1997-10-23 Neurocrine Biosciences, Inc. Ligand inhibitors of insulin-like growth factor binding proteins and methods of use therefor
ZA978334B (en) 1996-09-16 1999-03-16 Univ Dalhousie Use of IFG-I for the treatment of kidney disorders renal insufficiencies steriod toxicity and related indications
JP2001503064A (ja) 1996-11-06 2001-03-06 ジェネンテク，インコーポレイテッド 拘束されたラセンペプチドとその製法
AU7891098A (en) 1996-12-27 1998-07-31 Daiichi Pharmaceutical Co., Ltd. Method for elevating the concentration of free insulin-like growth factor
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
AR012894A1 (es) 1997-06-13 2000-11-22 Lilly Co Eli Formulacion de insulina en solucion estable, su uso para preparar un medicamento y proceso para la preparacion de la misma.
DE19757250A1 (de) 1997-12-22 1999-07-01 Forssmann Wolf Georg Prof Dr Insulin-like growth factor binding protein und seine Verwendung
EP1067959A2 (de) 1998-04-03 2001-01-17 Chiron Corporation Verwendung von igf1 zur behandlng von knorpelkrankheiten
JP2003522110A (ja) 1998-10-02 2003-07-22 セルトリックス ファーマシューティカルズ，インコーポレイテッド ガン治療のためのヌルｉｇｆ
AU6515499A (en) 1998-10-16 2000-05-08 Musc Foundation For Research Development Fragments of insulin-like growth factor binding protein and insulin-like growth factor, and uses thereof
EP1141015B1 (de) 1999-01-06 2009-07-15 Genentech, Inc. Mutierte varianten des insulin-ähnlichen wachstumsfaktor i (igf-i)
DE60016560T2 (de) 1999-01-06 2005-12-15 Genentech, Inc., South San Francisco Mutierte variante des insulin-ähnlichen wachstumsfaktor-i (igf-i)
WO2000069901A2 (en) 1999-05-19 2000-11-23 Xencor, Inc. Proteins with insulin-like activity useful in the treatment of diabetes
WO2008005985A2 (en) 2006-07-06 2008-01-10 Molecular Logix, Inc. Insulin-like growth factor-1 receptor antagonists

Also Published As

Publication number Publication date
WO2000040613A1 (en) 2000-07-13
ATE284415T1 (de) 2004-12-15
US20020160955A1 (en) 2002-10-31
ES2234560T3 (es) 2005-07-01
JP2002535968A (ja) 2002-10-29
JP3971108B2 (ja) 2007-09-05
EP1141014A1 (de) 2001-10-10
US8097587B2 (en) 2012-01-17
AU762351B2 (en) 2003-06-26
EP1141014B1 (de) 2004-12-08
DK1141014T3 (da) 2005-04-11
IL143866A0 (en) 2002-04-21
US20110003746A1 (en) 2011-01-06
IL143866A (en) 2009-11-18
JP2006328074A (ja) 2006-12-07
AU2224500A (en) 2000-07-24
CA2356109C (en) 2008-04-22
US7105167B2 (en) 2006-09-12
DE60016560T2 (de) 2005-12-15
CA2356109A1 (en) 2000-07-13
WO2000040613A9 (en) 2001-05-17
DE60016560D1 (de) 2005-01-13
US6403764B1 (en) 2002-06-11

Similar Documents

Publication Publication Date Title
PT1141014E (pt) Variante mutante do factor de crescimento semelhante a insulina (igf-i)
ZA992447B (en) Quinoxalinones as serine protease inhibitors.
ZA992448B (en) Quinoxalinones as serine protease inhibitors.
DK1141015T3 (da) Insulin-lignende vækstfaktor (IGF) I-mutantvarianter
AU6424394A (en) Protease variants
BR9811187A (pt) Composições detergentes compreendendo uma mananase e uma protease
EP1089752A4 (de) Alpha-keto oxadiazole als serinprotease inhibitoren
DK2322187T3 (da) Anvendelse af uridin i kombination med cholin til behandling af hukommelses-lidelser
DZ2285A1 (fr) Inhibiteurs de protéase de la cystéine.
GB2349180B (en) Inverted I.C.engine configuration
EA200300026A1 (ru) Аналоги глюкагоноподобного пептида-1
PT1165069E (pt) Composicao sinergistica antitumoral
AUPP051497A0 (en) Antimicrobial peptides
ATE449789T1 (de) Pacap-peptidanaloga
NO20025893L (no) Veksthormon sekretagoga
ZA992445B (en) Benzoxazinones/benzothiazinones as serine protease inhibitors.
GB9917909D0 (en) Cysteine protease inhibitors
CA2318398A1 (en) Novel peptides having biological activity
ZA971733B (en) Serine protease inhibitors.
ZA995201B (en) Stabilized protein compositions.
ZA971667B (en) Serine protease inhibitors.
ZA200101590B (en) Improved stability for injection solutions.
BG106316A (en) Ambroxol-containing lozenge
ID28463A (id) KOMPOSISI DENGAN KEMURNIAN TINGGI YANG TERDIRI DARI (7α, 17α)-17-HIDROKSI-7-METIL-19-NOR-17-PREGN-5(10)-EN-20-IN-3-ON
FI962435A0 (fi) N.N'-bis(2-hydroksibentsyyli)eteenidiamiini-N,N'-dietikkahapon johdannaiset kelatoivina aineina